Previously, we have demonstrated that multidrug-resistance-associated protein 1 (Mrp1) represents an activation marker for murine T h
Introduction
The ATP-binding cassette (ABC) transporter molecule Mrp1 was originally detected by virtue of its ability to extrude cytotoxic drugs from lung tumor cells (1) . We have previously shown that this molecule is constitutively expressed by cloned T h 2 cells, while it is absent on resting T h 1 cells (2) . T h 1 cells acquire Mrp1 upon stimulation (2, 3) . Using the fluorescent anion fluo-3 as a target for Mrp1, we showed that Mrp1 is a powerful marker for parasite-specific activated T h cells in vivo in the model system of murine leishmaniasis (2) . This protozoan parasite infects macrophages and causes a lethal infection with expansion of T h 2 cells in susceptible (e.g. BALB/c) mice, while resistant mice (e.g. FVB, C57BL/6) mount a T h 1 response with production of IFNc and spontaneously clear the infection (4) .
Many of the studies on Mrp1 have made use of the reagent MK571, considered to be specific for Mrp1. Several years ago, we demonstrated that MK571 is able to completely block activation of T h cells and, from this set of data, we concluded at the time that Mrp1 is relevant for murine T h cell activation (3) . Very recently, a report appeared in this journal that described a blocking activity of MK571 on activation of human T h cells (5) . Again, this activity was attributed to MRP1, the human homologue of murine Mrp1.
Given these published conclusions on the relevance of Mrp1 and MRP1 for T h cell activation, we decided to publish a set of 'negative' data accumulated in the last 3 years in our laboratory by using Mrp1-deficient mice. We show that T h cells from these mice are absolutely normal in their activation characteristics and produce normal levels of cytokines in vitro. Likewise, the course of leishmaniasis in these mice, both in the susceptible and the resistant genetic background, is normal. Interestingly, activation of Mrp1-deficient T h cells can be blocked by MK571 to the same extent as that of wild-type T h cells arguing for a target molecule of MK571 which is different from Mrp1.
Methods

Mice
Mrp1-deficient (mrp1
À/À ) mice of the FVB background were kindly provided by J. Wijnholds, Netherlands Cancer Institute, Amsterdam (6) . In our animal facility, these mice were backcrossed for six generations to the BALB/c background.
In the experiments, female mrp1 À/À mice or mrp1 +/À littermate controls were used at the age of 6-10 weeks.
Murine leishmaniasis
Mice were infected in the right hind footpad with Leishmania major promastigotes and the infection was monitored by measuring the lesion size, as described previously (7) . Determination of parasite burden and antigen-specific re-stimulation of T h cells from the lesion-draining lymph nodes in vitro were also performed according to published methods (7) . The cytokine contents in 48-h culture supernatants were measured by ELISA using reagents from Becton-Dickinson (BD).
T h cell stimulation and staining for Mrp1
Naive CD4 + T cells from FVB mice were purified using the MACS system, as described (8) . These cells were differentiated in T h 1 or T h 2 cells and re-stimulated in vitro, as reported (8) . At variance to the published protocol, all primary stimulations were performed in the presence of anti-CD28 (clone 37.51) at a concentration of 2.5 lg ml
À1
. Culture supernatants were harvested 24 h after re-stimulation and the amounts of IL-2, IL-4 and IFNc were tested by ELISA using reagents from BD. Expression of the T h cell activation markers CD44 and CD69 was measured by flow cytometry with directly conjugated antibodies from BD 24 and 48 h after primary stimulation using the FACScan and the CellQuest software (BD). In some experiments, culture supernatants were harvested and tested 48 h after primary stimulation for the presence of IL-2. Also, some cultures received the compound MK571 (Alexis, Gruenberg, Germany) at concentrations indicated in Fig. 5 . In the experiment described in Fig. 1, CD4 + T cells were stained for Mrp1 24 h after re-stimulation. To do this, the cells were fixed with PFA for 20 min, permeabilized by 0.5% saponin and stained using anti-Mrp1 antibody (1 lg ml
, kindly providid by R. J. Scheper, Free University Hospital, Amsterdam, The Netherlands) and PE-conjugated goat anti-rat antibodies (10 lg ml À1 , Dianova, Hamburg, Germany) followed by FACS analysis.
Results and Discussion
We have previously shown that Mrp1 represents an activation marker for T h 1 cells, while cloned T h 2 cells express Mrp1 constitutively (2) . MK571 was able to block activation of T h 1 cells which, at the time of the publication, led us to conclude that Mrp1 is required for T h 1 cell activation.
To confirm the relevance of Mrp1 for T h cell activation, we used the in vivo model of leishmaniasis in mice deficient for Mrp1. The lack of Mrp1 was confirmed by deficient intracellular staining for Mrp1 in activated T h cells of these mice as compared with T h cells from mrp1 +/À littermates (Fig. 1) . Surprisingly, the course of leishmaniasis did not differ between these mice and control gene-competent littermates, as measured by development of lesion size in the infected footpad. This was true for the resistant phenotype in mrp1 À/À FVB mice as well as for the susceptible phenotype in mrp1 À/À BALB/c mice (Fig. 2) . Like the lesion size, the parasite burden in the lesion-draining lymph nodes of these mice was unaltered with equally high burdens in lymph nodes of mrp1 À/À and mrp1 +/À BALB/c mice and equally low burdens in lymph nodes of mrp1 À/À and mrp1 +/À FVB mice (data not shown). Similar data were obtained when the parasite burden was tested 2 or 7 weeks after infection or when the infection was ) and soluble anti-CD28 (2.5 lg ml
À1
) for 72 h. After a resting phase in the absence of anti-CD3, but presence of IL-2, the cells were washed and re-stimulated (1 3 10 6 ml
) by immobilized anti-CD3 (5 lg ml À1 ). Twenty-four hours later, the cells were fixed, permeabilized and stained for expression of Mrp1 followed by FACS analysis. ) were infected with 2 3 10 7 Leishmania major promastigotes in the right hind footpad. As a parameter for lesion development, the relative increase in footpad thickness as compared with the non-infected contralateral footpad is shown. BALB/c mice were euthanized 5 weeks after infection due to necrosis of the lesion. Bars denote the SD of the increase in footpad thickness in each group. Two experiments were performed with similar results. initiated using 1 3 10 4 instead of 2 3 10 7 leishmania promastigotes (data not shown).
Weeks after infection
At different times after infection, single-cell preparations of the draining lymph nodes were re-stimulated in vitro with leishmania antigens and the cytokines produced were measured by ELISA. As shown for FVB mice 7 weeks after infection, cytokine production was dependent on the presence of leishmania antigens and followed the expected T h 1 cytokine pattern (high levels of IFNc but not IL-4, Fig. 3A) . In contrast, cytokines of a T h 2 pattern were secreted by cells from infected BALB/c mice 5 weeks after infection and, again, the amounts of cytokines did not differ between cells from mrp1 À/À and mrp1 +/À mice (Fig. 3B) . As for BALB/c-derived cells, no difference in cytokine production was noted in the presence or absence of exogenous leishmania antigens. This is a common finding in this mouse strain and can be attributed to the high parasite loads present in the lymph node preparations. Similar data were obtained when lymph node cells were tested 2 weeks after infection (data not shown).
In light of our previously published findings, these results were unexpected. To evaluate the role of Mrp1 for T h cell function independently, we next used a well established protocol to differentiate naive CD4
+ T h cells in T h 1 or T h 2 cells in vitro using anti-CD3 in conjunction with anti-CD28 and IL-12 plus anti-IL-4 or IL-4 plus anti-IFNc. After a resting period, the cells were re-stimulated by anti-CD3 and cytokines produced were measured by ELISA. As expected, IFNc but not IL-4 was produced by T h 1-driven cells (Fig. 4) , while the reverse was true for T h 2-driven cells. Again, no significant difference was noted between cells from mrp1 À/À and mrp1 +/À mice. In our previous publication published several years ago as well as in a very recent publication published in this journal about human T h cells, a blocking activity of the compound MK571 was used to conclude that Mrp1 or the human homologue MRP1 is relevant for T h cell activation (3, 5) . This conclusion is based on the assumption that MK571 is specific for Mrp1/MRP1. However, the results in the current publication strongly argue against a decisive role of Mrp1 for murine T h cell activation. Therefore, in the final set of experiments, we addressed the question whether MK571 would have a blocking capacity on the activation of mrp1 À/À T h cells. The results of a representative experiment are shown in Fig. 5 : Naive promastigote equivalents) for 48 h in triplicates and supernatants were tested for the depicted cytokines by ELISA. Each mouse was analyzed separately and the bars denote the SD for the different mice in one group. Two experiments were performed with similar results. 
CD4
+ mrp1 À/À T h cells were stimulated for 48 h by anti-CD3 and anti-CD28 in the presence or absence of MK571. Thereafter, IL-2 and IFNc production was tested in the culture supernatants. As can be seen, IL-2 and IFNc production was strictly dependent on anti-CD3/28. MK571 blocked IL-2 as well as IFNc secretion dose dependently. Remarkably, the amounts of MK571 necessary for suppression were exactly the same as those reported for murine mrp1 +/+ or human MRP1 +/+ T h cells. From this data, we would like to conclude that in contrast to previous conclusions, Mrp1 plays no major role for T h cell activation and that MK571 likely exerts its effects by targeting a molecule different from Mrp1. Of note, since our original analysis of Mrp1 function on T h cells, Mrp molecules have increased in number and now form a whole family of molecules in mice and humans (9) . It has already been shown that MK571 also suppresses the activities of Mrp4 and Mrp5 (10) . In addition, MK571 is also known to inhibit the ABC transporter abcg2 and the leukotriene D 4 receptor (LTD 4 R) (11, 12) . As for Mrp4, we have preliminary evidence using mrp4 À/À mice, that Mrp4 is also irrelevant for T h cell activation. In addition, we have used several other LTD 4 R antagonists and did not observe any effects of these compounds on T h cell activation. In conclusion, therefore, the molecular target which is used by MK571 to inhibit T h cell activation is still unknown and, quite likely, may represent a different member of the Mrp family. Despite this, our previous results on Mrp1 expression in T h cells and the role of Mrp1 as a marker for in vivo-activated T h cells (2) are still valid.
Our data challenge conclusions of the above cited paper by Zhang et al. (5) of a relevance of MRP1 for human T h cell function. Of course, we cannot exclude the possibility that human T h cells behave differently than murine T h cells in this regard or, alternatively, that our treatment protocol with anti-CD3/28 has somehow different effects than stimulation by superantigens, as performed by Zhang et al. (5) . Also, it should be mentioned that in other complex in vivo models, like dextran sulphate sodium-induced colitis, dendritic cell migration or drug-induced ear edema, mrp1 À/À mice had a phenotype (6, 13, 14) . However, in all these models, a major contribution to the respective model stems from cells other than T h cells. Thus, although the results obtained in these models may allow for the assumption of a subtle effect of Mrp1 in T h cells, they certainly do not prove it. 
